Trial reportThe British journal of psychiatry : the journal of mental science2008
Extrapyramidal side-effects of antipsychotics in a randomised trial.
Trial report in The British journal of psychiatry : the journal of mental science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 11 syntheses or guidelines pooled it, 267 citations in OpenAlex.
- Psychotic relapse prediction via biomarker monitoring: a systematic review.Frontiers in psychiatry · 2024Pooled it
- [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].Der Nervenarzt · 2019Pooled it
- Cholinergic medication for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018Pooled it
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.The Cochrane database of systematic reviews · 2018Pooled it
- Perphenazine for schizophrenia.The Cochrane database of systematic reviews · 2015Pooled it
- Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2013Pooled it
- Antipsychotic drug treatment for elderly people with late-onset schizophrenia.The Cochrane database of systematic reviews · 2012Pooled it
- Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.Schizophrenia bulletin · 2012Pooled it
- Pooled it
- The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.Schizophrenia bulletin · 2010Guideline
- Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009Pooled it
- Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study.Journal of translational medicine · 2023Trial
- Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.Clinical drug investigation · 2021Trial
- Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology · 2017Trial
- The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology · 2013Trial
- Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.Psychopharmacology · 2011Trial
- The association between weight change and symptom reduction in the CATIE schizophrenia trial.Schizophrenia research · 2011Trial
- Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.The Journal of clinical psychiatry · 2011Trial
- Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study.Translational psychiatry · 2026Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 2 countries.
Funding
Abstract
backgroundThere are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs.
aimsTo compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia.
methodIncidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted.
resultsThere were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing second-generation antipsychotics with perphenazine or comparing between second-generation antipsychotics. Secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine.
conclusionsThe incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.